nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—Spironolactone—dilated cardiomyopathy	0.348	1	CrCtD
Drospirenone—NR3C2—dilated cardiomyopathy	0.212	1	CbGaD
Drospirenone—NR3C2—Spironolactone—dilated cardiomyopathy	0.0973	0.462	CbGbCtD
Drospirenone—PGR—Spironolactone—dilated cardiomyopathy	0.0628	0.298	CbGbCtD
Drospirenone—AR—Spironolactone—dilated cardiomyopathy	0.0504	0.24	CbGbCtD
Drospirenone—Eplerenone—Spironolactone—dilated cardiomyopathy	0.034	0.159	CrCrCtD
Drospirenone—Potassium Canrenoate—Spironolactone—dilated cardiomyopathy	0.0257	0.12	CrCrCtD
Drospirenone—Megestrol acetate—Spironolactone—dilated cardiomyopathy	0.0236	0.11	CrCrCtD
Drospirenone—Medroxyprogesterone Acetate—Spironolactone—dilated cardiomyopathy	0.0209	0.0976	CrCrCtD
Drospirenone—Cortisone acetate—Spironolactone—dilated cardiomyopathy	0.0183	0.0854	CrCrCtD
Drospirenone—Testolactone—Spironolactone—dilated cardiomyopathy	0.0178	0.0829	CrCrCtD
Drospirenone—Progesterone—Spironolactone—dilated cardiomyopathy	0.0159	0.0742	CrCrCtD
Drospirenone—Testosterone Propionate—Spironolactone—dilated cardiomyopathy	0.0159	0.0742	CrCrCtD
Drospirenone—Methyltestosterone—Spironolactone—dilated cardiomyopathy	0.0155	0.0723	CrCrCtD
Drospirenone—Testosterone—Spironolactone—dilated cardiomyopathy	0.0138	0.0644	CrCrCtD
Drospirenone—Hydrocortisone—Spironolactone—dilated cardiomyopathy	0.013	0.0605	CrCrCtD
Drospirenone—NR3C2—ACE Inhibitor Pathway—MAS1—dilated cardiomyopathy	0.00185	0.195	CbGpPWpGaD
Drospirenone—NR3C2—ACE Inhibitor Pathway—AGTR2—dilated cardiomyopathy	0.000775	0.082	CbGpPWpGaD
Drospirenone—NR3C2—ACE Inhibitor Pathway—ACE—dilated cardiomyopathy	0.000661	0.07	CbGpPWpGaD
Drospirenone—NR3C2—ACE Inhibitor Pathway—AGTR1—dilated cardiomyopathy	0.000596	0.063	CbGpPWpGaD
Drospirenone—Eplerenone—NR3C2—dilated cardiomyopathy	0.000475	0.487	CrCbGaD
Drospirenone—Infarction—Lisinopril—dilated cardiomyopathy	0.000456	0.172	CcSEcCtD
Drospirenone—NR3C2—ACE Inhibitor Pathway—AGT—dilated cardiomyopathy	0.000419	0.0444	CbGpPWpGaD
Drospirenone—PGR—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.000363	0.0384	CbGpPWpGaD
Drospirenone—Breast pain—Spironolactone—dilated cardiomyopathy	0.000355	0.134	CcSEcCtD
Drospirenone—Spironolactone—NR3C2—dilated cardiomyopathy	0.000324	0.333	CrCbGaD
Drospirenone—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—dilated cardiomyopathy	0.000293	0.031	CbGpPWpGaD
Drospirenone—AR—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.000276	0.0292	CbGpPWpGaD
Drospirenone—PGR—Nuclear signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.000274	0.0289	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—ZBTB17—dilated cardiomyopathy	0.000259	0.0274	CbGpPWpGaD
Drospirenone—Thrombosis—Furosemide—dilated cardiomyopathy	0.000238	0.0901	CcSEcCtD
Drospirenone—NR3C2—cardiac ventricle—dilated cardiomyopathy	0.00023	0.116	CbGeAlD
Drospirenone—NR3C2—myocardium—dilated cardiomyopathy	0.000217	0.109	CbGeAlD
Drospirenone—BCHE—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.000202	0.0214	CbGpPWpGaD
Drospirenone—PGR—myocardium—dilated cardiomyopathy	0.000201	0.101	CbGeAlD
Drospirenone—Progesterone—NR3C2—dilated cardiomyopathy	0.000175	0.18	CrCbGaD
Drospirenone—AR—cardiac ventricle—dilated cardiomyopathy	0.000171	0.0859	CbGeAlD
Drospirenone—AR—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.000163	0.0172	CbGpPWpGaD
Drospirenone—AR—myocardium—dilated cardiomyopathy	0.000161	0.0808	CbGeAlD
Drospirenone—NR3C2—heart—dilated cardiomyopathy	0.000151	0.0762	CbGeAlD
Drospirenone—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000147	0.0557	CcSEcCtD
Drospirenone—Breast pain—Lisinopril—dilated cardiomyopathy	0.000145	0.0549	CcSEcCtD
Drospirenone—BCHE—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.000141	0.0149	CbGpPWpGaD
Drospirenone—PGR—heart—dilated cardiomyopathy	0.000141	0.0708	CbGeAlD
Drospirenone—BCHE—cardiac ventricle—dilated cardiomyopathy	0.000139	0.0699	CbGeAlD
Drospirenone—NR3C2—cardiac atrium—dilated cardiomyopathy	0.000129	0.0651	CbGeAlD
Drospirenone—AR—Nongenotropic Androgen signaling—RAC1—dilated cardiomyopathy	0.000126	0.0133	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000116	0.0123	CbGpPWpGaD
Drospirenone—AR—heart—dilated cardiomyopathy	0.000112	0.0564	CbGeAlD
Drospirenone—PTGS2—S1P1 pathway—RAC1—dilated cardiomyopathy	0.000107	0.0113	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	9.61e-05	0.0102	CbGpPWpGaD
Drospirenone—AR—cardiac atrium—dilated cardiomyopathy	9.58e-05	0.0482	CbGeAlD
Drospirenone—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	9.55e-05	0.0361	CcSEcCtD
Drospirenone—PGR—Cellular roles of Anthrax toxin—TNF—dilated cardiomyopathy	9.42e-05	0.00996	CbGpPWpGaD
Drospirenone—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	9.37e-05	0.0355	CcSEcCtD
Drospirenone—PGR—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	9.21e-05	0.00974	CbGpPWpGaD
Drospirenone—BCHE—heart—dilated cardiomyopathy	9.11e-05	0.0459	CbGeAlD
Drospirenone—AR—Nongenotropic Androgen signaling—RAF1—dilated cardiomyopathy	8.35e-05	0.00883	CbGpPWpGaD
Drospirenone—Breast disorder—Lisinopril—dilated cardiomyopathy	8.3e-05	0.0314	CcSEcCtD
Drospirenone—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—dilated cardiomyopathy	8.08e-05	0.00854	CbGpPWpGaD
Drospirenone—Erythema multiforme—Furosemide—dilated cardiomyopathy	8.01e-05	0.0303	CcSEcCtD
Drospirenone—BCHE—cardiac atrium—dilated cardiomyopathy	7.8e-05	0.0392	CbGeAlD
Drospirenone—Angiopathy—Furosemide—dilated cardiomyopathy	7.68e-05	0.0291	CcSEcCtD
Drospirenone—BCHE—Peptide hormone metabolism—ACE—dilated cardiomyopathy	7.07e-05	0.00748	CbGpPWpGaD
Drospirenone—Depression—Lisinopril—dilated cardiomyopathy	7.06e-05	0.0267	CcSEcCtD
Drospirenone—PTGS2—heart—dilated cardiomyopathy	7.02e-05	0.0354	CbGeAlD
Drospirenone—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	6.98e-05	0.0264	CcSEcCtD
Drospirenone—Myocardial infarction—Lisinopril—dilated cardiomyopathy	6.94e-05	0.0262	CcSEcCtD
Drospirenone—BCHE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	6.9e-05	0.0073	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—IL10—dilated cardiomyopathy	6.64e-05	0.00703	CbGpPWpGaD
Drospirenone—Nausea—Spironolactone—dilated cardiomyopathy	6.57e-05	0.0248	CcSEcCtD
Drospirenone—NR3C2—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	6.46e-05	0.00684	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	6.27e-05	0.00663	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	6.23e-05	0.0236	CcSEcCtD
Drospirenone—Erythema multiforme—Lisinopril—dilated cardiomyopathy	6.01e-05	0.0227	CcSEcCtD
Drospirenone—Nervous system disorder—Furosemide—dilated cardiomyopathy	5.9e-05	0.0223	CcSEcCtD
Drospirenone—Skin disorder—Furosemide—dilated cardiomyopathy	5.84e-05	0.0221	CcSEcCtD
Drospirenone—Angiopathy—Lisinopril—dilated cardiomyopathy	5.76e-05	0.0218	CcSEcCtD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	5.6e-05	0.00593	CbGpPWpGaD
Drospirenone—Mental disorder—Lisinopril—dilated cardiomyopathy	5.57e-05	0.0211	CcSEcCtD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	5.53e-05	0.00585	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—ABCC9—dilated cardiomyopathy	5.51e-05	0.00583	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—RAC1—dilated cardiomyopathy	5.42e-05	0.00573	CbGpPWpGaD
Drospirenone—PTGS2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	5.38e-05	0.00569	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—ACTN2—dilated cardiomyopathy	5.29e-05	0.00559	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—dilated cardiomyopathy	5.22e-05	0.00553	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	5.19e-05	0.0196	CcSEcCtD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	4.84e-05	0.00512	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	4.78e-05	0.00505	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	4.68e-05	0.0177	CcSEcCtD
Drospirenone—PTGS2—Overview of nanoparticle effects—TNF—dilated cardiomyopathy	4.64e-05	0.00491	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	4.55e-05	0.00481	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	4.54e-05	0.0048	CbGpPWpGaD
Drospirenone—BCHE—Peptide hormone metabolism—AGT—dilated cardiomyopathy	4.48e-05	0.00474	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	4.39e-05	0.00464	CbGpPWpGaD
Drospirenone—Skin disorder—Lisinopril—dilated cardiomyopathy	4.38e-05	0.0166	CcSEcCtD
Drospirenone—PGR—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	3.94e-05	0.00416	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	3.93e-05	0.00416	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—TAZ—dilated cardiomyopathy	3.93e-05	0.00416	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	3.93e-05	0.00416	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	3.9e-05	0.0147	CcSEcCtD
Drospirenone—PTGS2—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	3.59e-05	0.0038	CbGpPWpGaD
Drospirenone—Nausea—Furosemide—dilated cardiomyopathy	3.57e-05	0.0135	CcSEcCtD
Drospirenone—AR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	3.55e-05	0.00375	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	3.5e-05	0.0037	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	3.42e-05	0.00362	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	3.33e-05	0.00352	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—GJA1—dilated cardiomyopathy	3.26e-05	0.00345	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	3.13e-05	0.00331	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—NPPA—dilated cardiomyopathy	3.11e-05	0.00329	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	3.11e-05	0.00329	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	3.07e-05	0.00325	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—NR3C2—dilated cardiomyopathy	3.02e-05	0.00319	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	3e-05	0.00317	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	3e-05	0.00317	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	2.94e-05	0.00311	CbGpPWpGaD
Drospirenone—Nausea—Lisinopril—dilated cardiomyopathy	2.68e-05	0.0101	CcSEcCtD
Drospirenone—PTGS2—Spinal Cord Injury—RAC1—dilated cardiomyopathy	2.48e-05	0.00263	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—EGFR—dilated cardiomyopathy	2.46e-05	0.0026	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	2.4e-05	0.00254	CbGpPWpGaD
Drospirenone—AR—Gene Expression—NR3C2—dilated cardiomyopathy	2.3e-05	0.00243	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	2.29e-05	0.00242	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ANKRD1—dilated cardiomyopathy	2.15e-05	0.00228	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	2.14e-05	0.00226	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	2.11e-05	0.00223	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TAZ—dilated cardiomyopathy	2.03e-05	0.00214	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.95e-05	0.00206	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—NPPA—dilated cardiomyopathy	1.9e-05	0.002	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—SDHA—dilated cardiomyopathy	1.83e-05	0.00194	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	1.79e-05	0.00189	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	1.72e-05	0.00182	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	1.69e-05	0.00179	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	1.61e-05	0.00171	CbGpPWpGaD
Drospirenone—BCHE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	1.57e-05	0.00166	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—LMNA—dilated cardiomyopathy	1.55e-05	0.00164	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	1.5e-05	0.00158	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ANKRD1—dilated cardiomyopathy	1.48e-05	0.00157	CbGpPWpGaD
Drospirenone—AR—Gene Expression—NPPA—dilated cardiomyopathy	1.44e-05	0.00153	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TAZ—dilated cardiomyopathy	1.39e-05	0.00147	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	1.36e-05	0.00144	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.34e-05	0.00141	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—ACE—dilated cardiomyopathy	1.34e-05	0.00141	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.27e-05	0.00135	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—SDHA—dilated cardiomyopathy	1.26e-05	0.00133	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—RAF1—dilated cardiomyopathy	1.2e-05	0.00127	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.19e-05	0.00126	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—EGFR—dilated cardiomyopathy	1.13e-05	0.0012	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.12e-05	0.00119	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.12e-05	0.00118	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.09e-05	0.00115	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TNF—dilated cardiomyopathy	1.08e-05	0.00114	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.06e-05	0.00112	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.06e-05	0.00112	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.85e-06	0.00104	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.8e-06	0.00104	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.54e-06	0.00101	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—AGT—dilated cardiomyopathy	8.47e-06	0.000896	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.15e-06	0.000862	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.73e-06	0.000818	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NPPA—dilated cardiomyopathy	7.71e-06	0.000815	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.69e-06	0.000814	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.69e-06	0.000813	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	7.49e-06	0.000792	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PSEN2—dilated cardiomyopathy	7.46e-06	0.00079	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	7.32e-06	0.000774	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.74e-06	0.000713	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.64e-06	0.000703	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RAC1—dilated cardiomyopathy	6e-06	0.000635	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—AGT—dilated cardiomyopathy	5.73e-06	0.000606	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GPX1—dilated cardiomyopathy	4.98e-06	0.000526	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CD36—dilated cardiomyopathy	4.85e-06	0.000513	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—AGT—dilated cardiomyopathy	4.36e-06	0.000462	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RAF1—dilated cardiomyopathy	3.98e-06	0.000421	CbGpPWpGaD
Drospirenone—PTGS2—Disease—RAC1—dilated cardiomyopathy	3.75e-06	0.000397	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GPX1—dilated cardiomyopathy	3.43e-06	0.000362	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CD36—dilated cardiomyopathy	3.34e-06	0.000353	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—AGT—dilated cardiomyopathy	3e-06	0.000318	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EGFR—dilated cardiomyopathy	2.73e-06	0.000289	CbGpPWpGaD
Drospirenone—PTGS2—Disease—RAF1—dilated cardiomyopathy	2.49e-06	0.000263	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EGFR—dilated cardiomyopathy	1.71e-06	0.000181	CbGpPWpGaD
